Kodiak Sciences
Update in progressKOD (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on therapies for retinal diseases. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer in Phase 3 for retinal vascular diseases, including diabetic retinopathy, wet AMD, retinal vein occlusion, and diabetic macular edema. Preclinical programs include KSI-501 (IL-6 and VEGF-trap bispecific) and KSI-101 (KSI-501P) for retinal inflammation. Formerly Oligasis, renamed in 2015. Based in Palo Alto, CA.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Victor Perlroth M.D.
- Founded2009
- Employees141
- Websitekodiak.com
Identifiers
- ISINUS50015M1099
- FIGIBBG00BVR0D02
- LEI254900IXI5NI8C9OQE24
- CUSIP50015M109
- CIK0001468748